Can CG-0416 reduce fat without sacrificing muscle? CureGene begins first human test
CureGene has dosed the first participant in a randomized Phase 1 study of CG-0416, an oral liver-targeted THR-β prodrug whose weight-loss and muscle-preservation claims remain based on preclinical evidence.